The Antibody and BioResource (ABR) Core is a vibrant facility that contributes broadly to the basic and translational mission of the Center by focusing on two tools central to reproducibile research, specifically antibodies and cell lines. The Core works with researchers to develop new monoclonal antibodies (MAbs) against their target(s) of interest that will work in the required application(s). When antibodies are not readily available elsewhere, particularly newly developed at MSK, the facility provides access to essential MAbs by: 1) Producing (in vitro); 2) Purifying; 3) Conjugating (to fluorphores and proteins); and/or 4) Fragmenting them into Fab or F(Ab?)2 fragments. To promote the use of healthy cell cultures, which is central to generating reproducable data from these in vitro systems, the ABR Core offers a mycoplasma testing service. Well authenticated cell lines created at MSK and deposited into the Core are distributed to researchers around the world, which ensures the tools that the Cancer Center is sharing are of the highest quality. Relevant information and testing results on curated cell lines are also shared with recipients. These include, but are not limited to, a description and history of the line, references, culture conditions, unique characteristics, STR profiles for authentication purposes of human cell lines, images of the cells, confirmation that no mycoplasma was detectable in the culture, karyotyping, and appropriate flow cytometric analysis. During the past grant period the ABR Core has contributed to 50 publications for researchers from seven of the 10 CCSG Programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Ross, Gregory A; Rustenburg, Ariën S; Grinaway, Patrick B et al. (2018) Biomolecular Simulations under Realistic Macroscopic Salt Conditions. J Phys Chem B 122:5466-5486
Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7:
Sheckter, Clifford C; Panchal, Hina J; Razdan, Shantanu N et al. (2018) The Influence of Physician Payments on the Method of Breast Reconstruction: A National Claims Analysis. Plast Reconstr Surg 142:434e-442e
Yamazaki, Takashi; Liu, Lizhi; Lazarev, Denis et al. (2018) TCF3 alternative splicing controlled by hnRNP H/F regulates E-cadherin expression and hESC pluripotency. Genes Dev 32:1161-1174
Spaliviero, Massimiliano; Power, Nicholas E; Murray, Katie S et al. (2018) Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. Eur Urol 73:53-59
I??k, Mehtap; Levorse, Dorothy; Rustenburg, Ariën S et al. (2018) pKa measurements for the SAMPL6 prediction challenge for a set of kinase inhibitor-like fragments. J Comput Aided Mol Des 32:1117-1138
Rajshekar, Srivarsha; Yao, Jun; Arnold, Paige K et al. (2018) Pericentromeric hypomethylation elicits an interferon response in an animal model of ICF syndrome. Elife 7:
Aherne, Emily A; Pak, Linda M; Goldman, Debra A et al. (2018) Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics? Abdom Radiol (NY) 43:2665-2672
Wolner, Z J; Bajaj, S; Flores, E et al. (2018) Variation in dermoscopic features of basal cell carcinoma as a function of anatomical location and pigmentation status. Br J Dermatol 178:e136-e137
Rieth, Elizabeth F; Fischer, Gregory W; Afonso, Anoushka M (2018) Organization of Multidisciplinary Cancer Care for the Surgical Patient: Role of Anesthesiologists. Curr Anesthesiol Rep 8:368-374

Showing the most recent 10 out of 8799 publications